论文部分内容阅读
2项新的研究显示 ,诺华公司的芳香酶抑制剂来曲唑 (ｌｅｔｒｏｚｏｌｅ ,Ｆｅｍａｒａ)治疗绝经后妇女乳腺癌的疗效比他莫昔芬好。试验结果表明 ,来曲唑作为一线药物治疗晚期乳腺癌及用作手术前治疗以减少肿瘤体积的疗效优于他莫昔芬。来曲唑广泛用于他莫昔芬治疗无效的绝经后
Two new studies show that Novartis’s aromatase inhibitor letrozole (Femara) is more effective than Tamoxifen in the treatment of breast cancer in postmenopausal women. The results of the trial showed that letrozole is superior to tamoxifen as a first-line treatment for advanced breast cancer and as a preoperative treatment to reduce tumor volume. Letrozole is widely used after menopause to treat ineffective menopause